

Curriculum Vitae

Nationality: Turkish -British (Dual Citizenship)
 Date of Birth: 9 September 1966
 Languages: English and Turkish

Personal Profile	An experienced doctor (medical oncologist) with a sound knowledge of research methodology and data analysis. Dynamic and creative. Good communication skills.	
Postgraduate Qualifications and Education / Employment	Medical Park Hospital, Dept. of Medical Oncology	<i>Antalya-TURKEY (Apr. 2014- ...)</i>
	Degree: Director in Medical Oncology - acted as the head of oncology team	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (Sept. 2009 – Mar. 2014)</i>
	Degree: Professor in Medical Oncology (awarded in Sept. 2009) - acted as the head of medical oncology department	
	Gold Coast Hospital, Dept. of Hematology and Oncology	<i>Queensland-AUSTRALIA (Nov. 2007 – Sept. 2008)</i>
	Degree: Staff Specialist in medical oncology (full time) -acted as the leader of the medical oncology team, and involved in direct inpatient and outpatient care -participated in after hours and weekend on call roster -took part in Griffith University's medical students teaching program	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (Apr. 2002 – Sept. 2009)</i>
	Degree: Associate Professor in Medical Oncology (awarded in April 2002) - extensive involvement in teaching (theoretical and clinical) and research (in laboratory and clinical oncology) - direct patient care as the inpatient or outpatient consultant - an active member of the board of the electronmicroscopy unit, plans and integrates related clinical studies - continues to contribute to the training programme of oncology fellows	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (May 2000 – Apr. 2002)</i>
	Degree: Assistant Professor in Medical Oncology (awarded in May 2000) - extensive involvement in teaching (theoretical and clinical) and research (in laboratory and clinical oncology) - direct patient care as the inpatient or outpatient consultant - active contribution to the training programme of oncology fellows	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (Dec.1999 – May 2000)</i>
	Degree: Medical Oncologist (awarded in December 1999) - direct patient care in the inpatient or outpatient setting	
	Norfolk & Norwich Hospital, Clinical Oncology Department,	<i>Norwich-UK (Oct.1998 - Oct.1999)</i>
	Post: Clinical Oncology Fellowship / Registrarship - clinical training both at the Chemotherapy Unit and on the Oncology Ward - prescribed chemotherapy - held significant ward responsibilities including supervision of ward rounds with SMOs - supervised supportive and antineoplastic treatments - attended weekly interdisciplinary joint meetings.	
	Addenbrooke's Hospital, Clinical Oncology Department	<i>Cambridge-UK (Mar 1999 -Sep.1999)</i>
	Post: Visiting Oncology Fellowship - attended Dr. Helena Earl's sarcoma, breast and ovarian cancer clinics once in every fortnight	
	St. Bartholomew's Hospital, Medical Oncology Department,	<i>London-UK (Oct. 1997 - Oct. 1998)</i>
	Post: Visiting Research Fellowship - completed 3 studies including data collection and analysis and orally presented one of them in an international meeting. - regularly attended Prof Oliver's Outpatient Clinics and evaluated urinary system cancer patients - participated in daily ward rounds on a regular basis	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (Mar-Oct.1997 –Oct-Dec.1999)</i>
	Post: Oncology Fellowship - supervised junior staff - responsible from the oncology ward rounds and the management of the outpatients - provided oncology consultation for other departments. - attended seminars, literature discussion hours and weekly interdisciplinary oncology joint meetings.	
	Akdeniz University, School of Medicine,	<i>Antalya-TURKEY (Oct.1996 – Mar.1997)</i>
	Degree: Internal Medicine Specialist - saw patients with common cancers - followed oncology and internal medicine patients on the ward and at the outpatient clinics	

	Akdeniz University, School of Medicine, <i>Antalya-TURKEY (Nov.1991 – Oct.1996)</i> Post: Internal Medicine Residency (Top 1% standing in TUS-National Residency Examination) - co-supervised medical intensive care unit with selected emergency take for 16 months to gain expertise in acute, chronic conditions and invasive and non-invasive procedures - worked in emergency department with unselected emergency take for 7 months (including 2 months of emergency rotation during internship) - trained 4 junior internal medicine residents - directly involved in the care of patients in all subdivisions of internal medicine. Hacettepe University, School of Medicine (English), <i>Ankara-TURKEY (Sep. 1984 – July 1991)</i> Degree: MD (Top 1% standing in National University Entrance Examination) - held major clinical responsibilities including supervised prescription in urgent and elective conditions - internship in 7 disciplines	
Accreditation	Registration in Queensland for Medical Oncology <i>Queensland-AUSTRALIA, Oct. 2007</i> ESMO international examination of Medical Oncology (7th ranking in over 150 participants) Nice-FRANCE, Oct. 2002 British Council Sponsorship for General Medical Council (GMC) registration <i>London-UK, Jun. 1998</i> FMGEMS Examination Preclinics, Clinics, English (USA) <i>Ankara-TURKEY, Jan.1992</i>	
Memberships	• Founding member of Antalya Oncology Association (2007-...) • Founding member of Kamikaze Karate Club (2003-...) • Member of ESMO (European Society for Medical Oncology) (2002-...) • Member of ASCO (American Society of Clinical Oncology) (2002-...) • Member of TOG (Turkish Oncology Group) (2002-...)	
Awards	1. Medical oncology research award, 2nd place at the 22nd National Cancer Congress <i>Antalya-Turkey, Apr. 2017</i> 1. "Scientific research award, 1st place" at the 21st National Cancer Congress <i>Antalya-TURKEY, Apr. 2016</i> 2. "Nursing research award, 2nd place" at the 21st National Cancer Congress <i>Antalya-TURKEY, Apr. 2016</i> 3. "Special publication award" at the 21st National Cancer Congress <i>Antalya-TURKEY, Apr. 2016</i> 4. "Scientific research award, 2nd place" at the 20th National Cancer Congress <i>Antalya-TURKEY, Apr. 2015</i> 5. "Best scientific presentation award" in 5th Medical Oncology Congress <i>Antalya-TURKEY, Apr. 2014</i> 6. "Best poster award" in the 4th National Medical Oncology Congress <i>Antalya-TURKEY, Sep. 2007</i> 7. "Presentation award" in the 2nd National Oncology Research Meeting <i>Ankara-TURKEY, Jan. 2007</i> 8. "Palliative and social oncology research award, 3rd place" from the Novartis <i>Antalya-TURKEY, Apr. 2006</i> 9. "Best oncology research award" in the 1st Turkish Medical Oncology Congress <i>Antalya-TURKEY, Mar. 2006</i> 10. "Canada, Terry Fox cancer research award" via the Turkish Cancer Research Fund <i>Antalya-TURKEY, Mar. 2004</i> 11. "Scientific research award, 3rd place" from the Turkish Cancer Research Fund <i>Antalya-TURKEY, Apr. 2003</i> 12. "Best scientific presentation award" in 15th Turkish National Cancer Congress <i>Antalya-TURKEY, Apr. 2003</i>	
Other Professional Activities and Training	Member of Editorial Board of the Austin Journal of Lung Cancer Research <i>Antalya-TURKEY, Oct 2015</i> Was offered to give lecture in palliative care in oncology, ESMO course <i>Ankara-TURKEY, Nov. 2006</i> Co-chaired lung cancer session, ESMO educational meeting <i>Rhodes-GREECE, Jun 2004</i> St.Bartholomew's Hospital, Stem Cell Transplantation Unit <i>London-UK, Apr.-May 1998</i> St.Bartholomew's Hospital, Statistics Course Programme <i>London-UK, Jan.-Apr. 1998</i> St.Bartholomew's Hospital, Computer Course Programme <i>London-UK, Jan. 1998</i> The Royal Marsden NHS Trust, Seminar Course in Oncology <i>London-UK, Jan.-Apr. 1998</i> Emergency Medicine Training Program <i>Ankara-TURKEY, Sep. 1995</i> MSIC Radiology - TYKS Hospital <i>Turkey-FINLAND, Aug.1990</i>	
Additional Skills	Competence in medical statistics (both univariate and multivariate data analysis as well as advanced statistics)	
Publications	IN INTERNATIONAL INDEXES Papers: 1. Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Bozcuk H., Suleymanlar G., Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. <i>Advances in Peritoneal Dialysis. 1995;11: 119-22.</i> 2. Ustun H., Ersoy F.F., Sezer T., Ozean S., Bozcuk H., Yegin O., Balci M., Suleymanlar G., Yakupoglu G. Effect of Cefodizime on peritoneal mononuclear and polymorphonuclear cell chemotaxis. <i>Advances in Peritoneal Dialysis. 1998;14:154-7.</i> 3. Aslan M., Yucel G., Bozcuk H., Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. <i>Cancer Immunology Immunotherapy. 1998; 47(3):176-81.</i>	

4. **Bozcuk H.**, Turner B, Tsetis D., Thomas JM., Chan O., Reznick R., Ravi R., Hendry WF., Oliver RTD. The potential of day 21 CT scan and 3 dimensional construction in predicting need for post chemotherapy surgery in nonseminomatous germ cell tumour. *British Journal of Urology*, 2000; 86:707-13.
5. **Bozcuk H.**, Uslu G, Pestereli E, Samur M, Ozdogan M, Karaveli S, Sargin F, Savas B. Predictors of distant metastasis at presentation in Breast Cancer: A study also evaluating associations among common biological indicators. *Breast Cancer Research and Treatment* 2001; 68(3): 239-48.
6. **Bozcuk H.**, Martin C. Does treatment delay affect survival in non-small Lung Cancer? A retrospective analysis from a single U.K. centre. *Lung Cancer*, 2001; 34(2): 243-52.
7. Goonewardane T. I., **Bozcuk H.**, Oliver R.T.D., Barua J., Philip T., Mair G., Gibbs S. Phase $\frac{1}{2}$ study of synchronous Methotrexate, Cisplatin, Vincristine (MOPq10) chemotherapy and radiation for patients with locally advanced Bladder Cancer. *Urologia Internationalis*, 2001; 67: 293-7.
8. Samur M, **Bozcuk H.**, Kara A, Ozdogan M, Savas B. Factors associated with utilisation of unproven cancer therapies in Turkey. *Supportive Care in Cancer* 2001; 9(6): 452-8.
9. Ustun H, Ustun M, Sindel T, Yilmaz S, **Bozcuk H.**, Karpuzoglu G, Savas B. Lipiodol chemoembolization and additional tamoxifen and verapamil as chemosensitizers in unresectable hepatocellular carcinoma with immunohistochemically P-glycoprotein positive cases. *Turkish Journal of Cancer*, 2001; 31(2): 78-81.
10. **Bozcuk H.**, Erdogan V, Eken C, Cıplak E, Samur M, Ozdogan M, Savas B. Does awareness of diagnosis make any difference to quality of life? The determinants of emotional functioning in a group of cancer patients in Turkey. *Supportive Care in Cancer*, 2002; 10(1): 51-7.
11. Samur M, **Bozcuk H.**, Dalmaz G, Karaveli S, Köseoğlu FG, Çolak T, Peştereli E. Treatment delay in breast cancer; does it really have an impact on prognosis? *Turkish Journal of Cancer*, 2002; 32(4): 138-47.
12. **Bozcuk H.**, Kolağası O, Samur M, Yıldız M, Özdoğan M, Artaç M, Savas B. A brief information sheet on opioid effects improves quality of life in cancer patients on opioids. *Internet journal of pain, symptom control and palliative care*, 2003; 2(2).
13. Samur M, **Bozcuk H.** A paradigm shift in adjuvant treatment of receptor positive premenopausal breast cancer patients? Not yet! (Letter to the editor). *Journal of Clinical Oncology*, 2003; 21(12): 2444.
14. Özdoğan M, Samur M, **Bozcuk H.**, Sagtas E, Yıldız M, Artaç M, Savas B. Durable remission of leptomeningeal metastasis of breast cancer with letrozole; a case report and implications of biomarkers on treatment selection. *Japanese Journal of Clinical Oncology*, 2003; 33: 229-31.
15. Coban E, Samur M, **Bozcuk H.**, Ozdogan M. The value of CEA and CA19-9 in detecting cancer in a group of "High Risk" subjects with gastrointestinal symptoms. *International Journal of Biological Markers*, 2003; 18 (3): 177-81.
16. Samur M, **Bozcuk H.**, Karaveli S, Peştereli E, Özdoğan M, Yıldız M, Artaç M, Savas B. Reevaluation of baseline staging tests in breast cancer; what should be the standard? *Turkish Journal of Cancer*, 2003; 33(3):150-3.
17. Samur M, Karaveli S, **Bozcuk H.**, Pestereli E, Ozdogan M, Yıldız M, Artaç M, Savas B. A novel method of reporting c-erb-B2 overexpression: correlation with grade but not with other prognostic parameters in breast cancer. *Turkish Journal of Medical Sciences*, 2003, 33: 363-8.
18. Coban E, Ozdogan M, Tuncer M, **Bozcuk H.**, Ersoy F. The Value of Low-Dose Intraperitoneal Immunoglobulin administration in the treatment of Peritoneal Dialysis Related Peritonitis. *Journal of Nephrology*, 2004; 17(3): 427-430.
19. Sanlioglu A, Aydin C, **Bozcuk H.**, Terzioğlu E, Luleci G, Sanlioglu S. Fundamental principles of tumor necrosis factor- α gene therapy approach and implications for patients with lung carcinoma. *Lung Cancer*, 2004; 44 (2): 199-211.
20. Ozdogan M, Samur M, **Bozcuk H.**, Coban E, Artaç M, Kara A, Topcu Z, Sualp Y, Savas B. Do not tell approach: which factors affect relatives' attitudes against honest disclosure of diagnosis to cancer patients? *Supportive Care in Cancer*, 2004; 12 (7): 497-502.
21. **Bozcuk H.**, Koyuncu E, Yıldız M, Samur M, Özdoğan M, Artaç M, Çoban E, Savas B. A simple and accurate prediction model to estimate the intrahospital mortality risk for hospitalised cancer patients. *International Journal of Clinical Practice*, 2004; 58 (11):1014-1019.
22. **Bozcuk H.**, Bilge U, Koyuncu E, Gulkesen H. An application of Genetic Algorithm in conjunction with other data mining methods for estimating outcome after hospitalization in cancer patients. *Medical Science Monitor*, 2004; 10(6): CR246-251.
23. **Bozcuk H.**, Uslu G, Samur M, Yıldız M, Ozben T, Ozdogan M, Artaç M, Altunbas H, Akan I, Savas B. Tumor Necrosis Factor- α , Interleukin-6 and fasting serum insulin correlate with clinical outcome in metastatic breast cancer patients treated with chemotherapy. *Cytokine*, 2004; 27 (2-3): 58-65.
24. Ozdogan M, Samur M, **Bozcuk H.**, Aydin H, Coban E, Savas B. Venlafaxine for treatment of chemotherapy induced neuropathic pain. *Turkish Journal of Cancer*, 2004; 34 (3): 110-113.
25. Ozdogan M, Samur M, **Bozcuk H.**, Coban E, Artaç M, Savas B. Is the third line chemotherapy feasible for non small cell lung cancer? A retrospective study. *Turkish Journal of Cancer*, 2004; 34(1):19-23.
26. **Bozcuk H.**, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Artaç M, Ozdogan M, Samur M, Kaya A, Savas B. Cluster analysis of p-glycoprotein, c-erb-B2 and P53 in relation to tumor histology strongly indicates prognosis in patients with operable non-small cell lung cancer. *Medical Science Monitor*, 2005; 11 (6): HY11-20.
27. Artaç M, **Bozcuk H.**, Ozdogan M, Demiral AN, Sarper A, Samur M, Savas B. Different clinical features of primary and secondary tumours in patients with multiple malignancies. *Tumori*, 2005; 91(4):317-320.
28. **Bozcuk H.**, Artaç M, Ozdogan M, Savas B. Does maintenance / consolidation chemotherapy have a role in the management of small cell lung cancer (SCLC)? A meta-analysis of the published randomized controlled trials. *Cancer*, 2005; 104(12): 2650-2657.
29. Yıldız M, Ozenci CC, Akan I, Akan S, Sati L, Demir R, Savas B, Ozben T, Samur M, Ozdogan M, Artaç M, **Bozcuk H.** Zoledronic acid induces apoptosis in vitro: its association with Multidrug Resistance Protein-1 and evidence for synergy with vinblastine. *Cell Biology International*, 2006; 30(3): 278-282.
30. **Bozcuk H.**, Dalmis B, Samur M, Ozdogan M, Artaç M, Savas B. Quality of life in patients with advanced non-small cell lung cancer. *Cancer Nursing*, 2006; 29(2): 104-110.

31. **Bozcuk H**, Artac M, Kara A, Ozdogan M, Sualp Y, Topcu Z, Karaagaceli A, Yildiz M, Savas B. Does music exposure during chemotherapy improve quality of life in early breast cancer patients? : a pilot study. *Medical Science Monitor*, 2006; 12(5): CR200-205.
32. Yildiz M, **Bozcuk H**, Aslan A, Simsek T, Zorlu G, Artac M, Ozdogan M, Savas B, Samur M. Retrospective evaluation of weekly docetaxel in recurrent ovarian cancer: a single centre experience. *The internet journal of gynecology and obstetrics*, 2006; 6(1).
33. Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, **Bozcuk HS**. Factors related to truth-telling practice of physicians treating patients with cancer in Turkey. *Journal of palliative medicine*, 2006; 9(5): 1114 -1119.
34. Bulent Y, Zengin N, Aydin F, Ilhan M, Isikdogan A, Demir G, Aykan F, Celik I, Dane F, Ustuner Z, Boruban MC, **Bozcuk H**, Coskun HS, Karaoglu A, Altinbas M, Yamac D, Tek I, Budakoglu B, Utkan G, Ozdemir F, Aksoy F, Ozdemir F, Aksoy S, Ozdemir N, Akbulut H, Buyukcelik A, Icli F. The clinical and pathological features of patients with gastric cancer in Turkey. A Turkish Oncology Group Study. *Turkish Journal of Cancer*, 2006; 36(3):108-115
35. Ozdogan M, **Bozcuk H**, Coban E. Low grade inflammation in white coat hypertension. *Medical Science Monitor*, 2007; 13(12): CR570-573.
36. Ozturk OH, **Bozcuk H**, Burgucu D, Ekinci D, Ozdogan M, Akca S, Yildiz M. Cisplatin cytotoxicity is enhanced with zoledronic acid in A549 lung cancer cell line. Preliminary results of an in vitro study. *Cell Biology International*, 2007; 31(9): 1069-1071.
37. **Bozcuk H**, Gumus A, Ozbilim G, Sarper A, Kucukosmanoglu I, Ozdogan M, Demircan A. Recursive partitioning analysis of mediastinal N2 lymph node involvement with selected biomarkers in operable non-small cell lung cancer: A correlative study. *Biomarker Insights*, 2007; 2: 1-6.
38. Artac M, **Bozcuk H**. The debate over maintenance is not over in small cell lung cancer (Letter to the editor). *Journal of Clinical Oncology*, 2007; 25(36): 5840.
39. Korcum AF, Aksu G, **Bozcuk H**, Pestereli E, Simsek T. Small cell carcinoma of the cervix: a case report. *Archives of Gynecology and Obstetrics*, 2008; 277(4): 367-370.
40. Aksu MG, **Bozcuk HS**, Korcum AF. Effect of complementary and alternative medicine during radiotherapy on radiation toxicity. *Support Care Cancer*, 2008; 16(4): 415-419.
41. Artac M, **Bozcuk H**, Afacan B, Ozdogan M, Samur M. The impact of waist to hip ratio on clinical outcomes in metastatic breast cancer patients treated with aromatase inhibitors. *Breast*, 2008; 17(4): 418-422.
42. Aksu MG, **Bozcuk H**, Korcum AF, Sen CA, Tuncel N. The results of postoperative chemoradiotherapy in rectal cancer. *Turkish Journal of Cancer*, 2008; 38(1): 5-11.
43. Artac M, Pehlivan S, Akcan S, Pehlivan M, Tekinalp G, Itirli G, Aksoy N, Ozdogan M, Savas B, **Bozcuk H**. The role of microsatellite instability to predict clinical benefit from irinotecan based regimens in metastatic colorectal cancer. *Turkish Journal of Cancer*, 2008; 38(2): 49-56.
44. Artac M, **Bozcuk H**, Pehlivan S, Akcan S, Pehlivan M, Sever T, Ozdogan M, Savas B. The value of XPD and XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma patients with irinotecan based regimens. *J Cancer Res Clin Oncol*, 2010; 136(6): 803-809.
45. **Bozcuk H**, Artac M, Ozdogan M. Correlates of benefit from neoadjuvant chemotherapy before radiotherapy in non-small cell lung cancer: a meta-analytical approach with meta-regression analysis. *JBUION*, 2010; 15(1): 43-50.
46. Pehlivan S, Artac M, Sever T, **Bozcuk H**, Kilincarslan C, Pehlivan M. Gene methylation of SFRP2, P16, DAPK1, HIC1, and MGMT and KRAS mutations in sporadic colorectal cancer. *Cancer Genet Cytogenet*, 2010; 201(2): 128-132.
47. Coskun HS, Kargi A, Ozdogan M, **Bozcuk H**, Savas B. Leukocytosis, thrombocytosis and hypercalcemia as a triple paraneoplastic syndrome in a patient with squamous cell carcinoma of the renal pelvis. *Turk J Hematol*, 2010; 27: 51-52.
48. Sarper A, Titiz TA, Oz N, Arslan G, **Bozcuk H**, Demircan A. Results of carinal sleeve lobectomy and sleeve pneumonectomy for lung carcinoma. *Turkish J Thorac Cardiovasc Surg*, 2010; 18(4): 293-299.
49. **Bozcuk H**, Ozdogan M, Aykurt O, Topcuoglu F, Ozturk H, Ekinci D, Karadeniz A, Mutlu A, Burgucu D. Urticaria Mariuina (L.) Baker (Liliaceae) extract induces more cytotoxicity than standard chemotherapeutics in the A549 non-small cell lung cancer cell line. *Turk J Med Sci*, 2011; 41(1): 101-108.
50. **Bozcuk H**, Ozdogan M. The predictors of the efficacy of high dose chemotherapy and stem cell support in the management of metastatic germ cell cancer. *Bratisl Lek Listy*, 2011; 112(5): 296-304.
51. Artac M, **Bozcuk H**, Kiyici A, Eren OO, Boruban MC, Ozdogan M. Serum leptin level and waist to hip ratio predict the overall survival of metastatic breast cancer patients treated with aromatase inhibitors. *Breast Cancer*, 2011; Dec 28 (Epub ahead of print).
52. Tatli AM, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, Coskun HS, **Bozcuk H**, Savas B. Primary mucinous adenocarcinoma of the bladder: complete response with FOLF4 regimen. *Med Oncol*, 2012; 29(3): 1935-1937.
53. Senol Y, Ozdogan M, **Bozcuk H**. Effects and permanency of the training program "Communication with cancer patients" on the opinions of the students. *J Cancer Educ*, 2012; 27(2): 338 -341.
54. Uysal M, Goksu SS, Coskun HS, Savas B, Ozdogan M, **Bozcuk H**. Intraarticular hemorrhage due to Bevacizumab in a patient with metastatic colorectal cancer: a case report. *J Med Case Rep*, 2012; 6(1): 188. doi: 10.1186/1752-1947-6-188.
55. **Bozcuk H**, Abali H, Coskun S. Lung Cancer Committee of Turkish Oncology Group. The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis. *World J Surgical Oncol*, 2012; 10(1): 161. doi: 10.1186/1477-7819-10-161.
56. Kavradim ST, Ozer ZC, **Bozcuk H**. Hope in people with cancer: a multivariate analysis from Turkey. *J Adv Nurs*, 2013; 69(5): 1183-1196.
57. Gunduz S, Elpek GO, Uysal M, Goksu SS, Tatli M, Arslan D, Coskun HS, **Bozcuk H**, Savas B, Ozdogan M. Coexistence of gastric adenocarcinoma and choriocarcinoma: complete response to trastuzumab and chemotherapy. *Case Rep Oncol*, 2012; 5(2):394-399.
- 58- Arslan D, Gunduz S, Tural D, Uysal M, Tatli AM, Baysogun Cİ, Elpek GÖ, Coskun HS, **Bozcuk HS**, Savas B. Inflammatory myofibroblastic tumor: a rarely seen submucosal lesion of the stomach. *Case Rep Oncol Med*, 2013; 2013:328108. doi: 10.1155/2013/328108.

- 59- Zeybek A, Toru S, Ozbudak IH, Sarper A, Oz N, **Bozcuk H**, Ozbilim G, Demircan A. Clinical and pathologic prognostic factors that are influential in the survival and prognosis of lung adenocarcinomas and invasive predominant subtypes. *Int Surg*. 2013;98(3):191-199.
- 60- Kargi A, Uysal M, **Bozcuk H**, Coskun HS, Savas B, Ozdogan M. The importance of COX-2 expression as prognostic factor in early breast cancer. *JBUON*. 2013;18(3):579-584.
- 61- Uysal M, **Bozcuk H**, Karakiline H, Goksu S, Tatli AM, Gunduz S, Arslan D, Coskun HS, Savas B. Pesticides and cancer: the first incidence study conducted in Turkey. *J Environ Pathol Toxicol Oncol*. 2013;32(3):245-249.
- 62- Yildiz M, **Bozcuk H**, Tokgun O, Karagur ER, Aykurt O, Akca H. Cyclamen exerts cytotoxicity in solid tumor cell lines: a step towards new cancer agents? *Asian Pac J Cancer Prev*. 2013; 14(10): 5911-5913.
- 63- Uysal M, **Bozcuk H**, Sezgin Goksu S, Murat Tatli A, Arslan D, Gunduz S, Senol Coskun H, Ozdogan M, Savas B. Basal proteinuria as a prognostic factor in patients with metastatic colorectal cancer treated with bevacizumab. *Biomed Pharmacother*. 2014 May;68(4):409-412.
- 64- Arican A, Bozkurt T, **Bozcuk H**, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel U, Uygur K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. *Support Care Cancer*. 2014; 22(10):2629-2634.
- 65- Arslan D, **Bozcuk H**, Gunduz S, Tural D, Tatli AM, Uysal M, Goksu SS, Bassorgun CI, Koral L, Coskun HS, Ozdogan M, Savas B. Survival results and prognostic factors in T4 N0-3 non-small cell lung cancer patients according to the AJCC 7th edition staging system. *Asian Pac J Cancer Prev*. 2014;15(6):2465-2472.
- 66- Artaç M, Turhal NS, Kocer M, Karabulut B, **Bozcuk H**, Yalcin S, Karagaac M, Gunduz S, Isik N, Uygur K. Do high-risk features support the use of adjuvant chemotherapy in stage II colon cancer? A Turkish Oncology Group study. *Tumori*. 2014;100(2):143-148.
- 67- Gunduz S, Mutlu H, Uysal M, Coskun HS, **Bozcuk H**. Prognostic value of hematologic parameters in patients with metastatic renal cell carcinoma using tyrosine kinase inhibitors. *Asian Pac J Cancer Prev*. 2014;15(8):3801-3804.
- 68- Goksu SS, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, **Bozcuk H**, Ozdogan M, Coskun HS. Use of blood transfusion at the end of life: does it have any effects on survival of cancer patients? *Asian Pac J Cancer Prev*. 2014;15(10):4251-4254.
- 69- Mutlu H, Gunduz S, Buyukcelik A, Yildiz O, Uysal M, Tural D, **Bozcuk H**, Coskun HS. The necessity of cytoreductive nephrectomy in patients with metastatic renal cell carcinoma using antiangiogenic targeted therapy after interferon alfa-2b. *Clin Genitourin Cancer*. 2014 Dec;12(6):447-450.
- 70- Arslan D, Uysal M, Tatli AM, Gunduz S, Goksu SS, Bassorgun CI, Coskun HS, **Bozcuk H**, Savas B. Her-2 positive gastric cancer presented with thrombocytopenia and skin involvement: a case report. *Case Rep Oncol Med*. 2014;2014:194636. doi: 10.1155/2014/194636.
- 71- Tatli AM, Coskun HS, Uysal M, Arslan D, Sezgin Goksu S, Guvenay Gunduz S, Cakal S, **Bozcuk H**, Savas B. Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. *Int J Clin Exp Med*. 2014;7(8):2191-2196.
- 72- Gunduz S, Mutlu H, Uysal M, Coskun HS, **Bozcuk H**. Elucidating the correlation between treatment with tyrosine kinase inhibitors and mean platelet volume in patients with metastatic renal cell cancer. *Oncol Lett*. 2014;8(5):2249-2252.
- 73- Arslan D, Koca T, Tastekin D, Basaran H, **Bozcuk H**. Impact of poster presentations on academic knowledge transfer from the oncologist perspective in Turkey. *Asian Pac J Cancer Prev*. 2014;15(18):7707-7711.
- 74- Gunduz S, Mutlu H, Goksu SS, Arslan D, Tatli AM, Uysal M, Coskun HS, **Bozcuk H**, Ozdogan M, Savas B. Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma. *Asian Pac J Cancer Prev*. 2014; 15(20):8843-8846.
- 75- Goksu SS, **Bozcuk H**, Uysal M, Ulukal E, Ay S, Karasu G, Soydas T, Coskun HS, Ozdogan M, Savas B. Determinants of opioid efficiency in cancer pain: a comprehensive multivariate analysis from a tertiary cancer centre. *Asian Pac J Cancer Prev*. 2014;15(21):9301-9305.
- 76- **Bozcuk H**, Yildiz M, Artaç M, Kocer M, Kaya C, Ulukal E, Ay S, Kılıç MP, Şimşek Fİİ, Kılıç Aya P, Uçar S, Coskun HS, Savas B. A prospectively validated nomogram for predicting the risk of chemotherapy-induced febrile neutropenia: a multicenter study. *Support Care Cancer*. 2015;23(6):1759-1767.
- 77- Sezgin Goksu S, Gunduz S, Unal D, Uysal M, Arslan D, Tatli AM, **Bozcuk H**, Ozdogan M, Coskun HS. Use of chemotherapy at the end of life in Turkey. *BMC Palliat Care*. 2014;13(1):51. doi: 10.1186/1472-684X-13-51. eCollection 2014.
- 78- Yildirim M, Duman E, Ozturk TT, Kaya V, Parlak C, Varol U, Kaya K, Yildiz M, **Bozcuk H**. Cancer patients' level of knowledge about diseases and their expectations from their oncologists. *TAF preventive Medicine Bulletin*. 2014;13(6):465-468.
- 79- Gunduz S, Ozturk O, **Bozcuk H**, Coskun HS, Ozdogan M, Erkilic M, Sindel T, Yildiz A, Yilmaz S, Boza A, Aydin F, Karavalcin B, Savas B. Yttrium-90 radioembolization in patients with unresectable liver metastases: determining the factors that lead to treatment efficacy. *Hepatogastroenterology*. 2014;61(134):1529-1534.
- 80- Uysal M, Ozdogan M, Kargi A, Gunduz S, Sezgin Goksu S, Murat Tatli A, Arslan D, Mutlu H, Senol Coskun H, **Bozcuk H**. Prolonged progression-free survival with maintenance metronomic oral cyclophosphamide and etoposide treatment in macroscopic residual disease or recurrent/advanced stage ovarian cancer. *JBUON*. 2014;19(4):980-984.
- 81- Demirelli S, Erkilic M, Oner AO, Budak ES, Gunduz S, Ozturk O, **Bozcuk H**, Sindel HT, Boz A. Evaluation of factors affecting tumor response and survival in patients with primary and metastatic liver cancer treated with microspheres. *Nucl Med Commun*. 2015;36(4):340-349.
- 82- Geredeli C, Artaç M, Yildirim S, Inal A, Dede I, Gul T, Boruban MC, Koral L, Karaagac M, Zamani AG, Altinok T, Aribas O, **Bozcuk H**, Demirkazık A. Prognostic value of ERCC1, ERCC2, XRCC1, and TP53 single nucleotide polymorphisms in patients with early-stage non-small cell lung cancer. *Tumour Biol*. 2015;36(6):4279-4285.
- 83- Yildirim M, Kaya V, Demirpence O, Gunduz S, **Bozcuk H**. Prognostic significance of p53 in gastric cancer: a meta-analysis. *Asian Pac J Cancer Prev*. 2015;16(1):327-332.

- 84- Mutlu H, Arslan D, Gündüz S, Tural D, Büyükcelik A, Cihan YB, Aslan T, **Bozcuk H**, Coşkun HS. The Optimal Treatment Modality in Patients with T4N2M0 Non-Small Cell Lung Cancer: The Best Choice May Be Definitive Chemoradiotherapy Followed by Consolidation Chemotherapy. *Chemotherapy*. 2014;60(2):107-111
- 85- Gunduz S, Mutlu H, Tural D, Yıldız Ö, Uysal M, Coşkun HS, **Bozcuk H**. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. *AsiaPac J Clin Oncol*. 2015. doi: 10.1111/ajco.12358. [Epub ahead of print]
- 86- Arslan D, Tural D, Koca T, Tastekin D, Kaymak Cerksefi A, Basaran H, Gunduz S, Murat Tatli A, Sezgin Goksu S, Uysal M, Kargi A, Kargi B, Koral L, Ibrahim Bassorgun C, Unal D, Mutlu H, Senol Coskun H, Ozdogan M, **Bozcuk H**. Prognostic factors in clinical stage T4N2 locally advanced non-small cell lung cancer. *JBUON*. 2015;20(2):573-579.
- 87- Mutlu H, Musri FY, Yalçın M, Kargi A, Özdoğan M, **Bozcuk H**. Metronomic oral chemotherapy with old agents in patients with heavily treated metastatic breast cancer. *J Cancer Res Ther*. 2015;11(2):287-290.
- 88- Tural D, Kivrak SD, Mutlu H, Erkeci M, Gunduz S, Karakurt M, Musri F, Tuna S, Boz A, Aydın F, Karayalcin B, **Bozcuk H**, Senol CH. Is there any relation between PET-CT SUVmax value and prognostic factors in locally advanced breast cancer? *J BUON*. 2015;20(5):1282-1286.
- 89- Gündüz S, Göksu SS, Arslan D, Tatli AM, Uysal M, Gündüz UR, Sevinç MM, Coşkun HS, **Bozcuk H**, Mutlu H, Savas B. Factors affecting disease-free survival in patients with human epidermal growth factor receptor 2-positive breast cancer who receive adjuvant trastuzumab. *Mol Clin Oncol*. 2015;3(5):1109-1112.
- 90- Tatli AM, Arslan D, Uysal M, Goksu SS, Gunduz SG, Coskun HS, Ozdogan M, Savas B, **Bozcuk HS**. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer. *J Cancer Res Ther*. 2015;11(4):805-809.
- 91- Göksu SS, **Bozcuk H**, Koral L, Çakar B, Gündüz S, Tatli AM, Arslan D, Uysal M, Koçer M, Artaç M, Karabulut B, Coşkun HS, Özdoğan M, Savas B. Factors predicting lapatinib efficacy in HER-2+ metastatic breast carcinoma: Does it work better in different histologic subtypes? *Indian J Cancer*. 2015;52(4):517-519.
- 92- Gunduz S, **Bozcuk H**, Yıldız M, Goksu SS, Uysal M, Arslan D, Tatli AM, Mutlu H, Coşkun HS, Ozdogan M. Line of abiraterone acetate in castration-resistant metastatic prostate cancer - Does it matter? report of a multi-institutional experience. *Indian J Cancer*. 2015;52(4):658-660.
- 93- Turkoglu MA, Vural V, Erbis H, Coskun HS, **Bozcuk H**, Ibis M. Liver first approach as an unusual treatment modality for rectal cancer with synchronous liver metastasis: report of a case. *Gazi Med J*. 2015; 26(3): 117-118.
- 94- Merdin A, Merdin FA, Gunduz S, **Bozcuk H**, Coskun HS. Opioid endocrinopathy: a clinical problem in patients with cancer pain. *Exp Ther Med*. 2016;11(5):1819-1822.
- 95- Artaç M, Coskun HS, Korkmaz L, Kocer M, Turhal NS, Engin H, Dede I, Paydas S, Oksuzoglu B, **Bozcuk H**, Demirkazık A. Using Interferon alpha before Thyrosine kinase inhibitors may increase survival in patients with metastatic renal carcinoma: a Turkish Oncology Group (TOG) study. *Clin Genitourin Cancer*. 2016; 14(4):347-353.
- 96- Artaç M, Uysal M, Karaagac M, Korkmaz L, Er Z, Guler T, Boruban MC, **Bozcuk H**. Prognostic impact of neutrophil/lymphocyte ratio, platelet count, CRP and albumin levels in metastatic colorectal cancer patients treated with FOLFIRI-Bevacizumab. *J Gastrointest Cancer*. 2017;48(2):176-180.
- 97- **Bozcuk H**, Özcan K, Erdogan C, Mutlu H, Demir M, Coskun S. A comparative study of art therapy in cancer patients receiving chemotherapy and improvement in quality of life by watercolour painting. *Complementary Therapies in Medicine*. 2017;30: 67-72.
- 98- Gligorov J, Ataseven B, Verrill M, et al; SafeHer Study Group. Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. *Eur J Cancer*. 2017;82:237-246.

Abstracts:

1. Ersoy F.F., Karayalcin U., Karayalcin B., Sapan M., Suleymanlar G., **Bozcuk H.**, Yakupoglu G. Transfer of Native Insulin through the Peritoneal Membrane during CAPD in Diabetic and Non-Diabetic Patients. *Abstracts of the 15th Annual CAPD Conference*. 1995; 15:1.
2. Sapan M., **Bozcuk H.**, Akbulut M., et al. Peritoneal Equilibration Test (PET) in CAPD patients. *Kidney Int* 48: (5), 1681-1681, 1995.
3. Aslan M., Yucel G., **Bozcuk H.**, Savas B. The effect of recombinant human granulocyte/macrophage-colony-stimulating factor (rHu GM-CSF) and rHu G-CSF administration on neutrophil chemiluminescence assay in patients following cyclic chemotherapy. *Free Radical Bio Med* 25:115-115, Suppl. 1, 1998.
4. **Bozcuk H.**, Turner B., Chan O., Reznick R., Ravi R., Hendry W. F., Oliver R.T.D. The response on CT 21 days after chemotherapy as a predictor of the need for surgery in germ cell cancer. *The Brit J Urol*, Vol.81, (Suppl. 3), 1998; 5.
5. Ustun H., Ersoy F.F., **Bozcuk H.**, Akca S., Sezer T., Suleymanlar G., Yakupoglu G. The effect of Cefodizime on peritoneal neutrophil and monocyte chemotaxis in CAPD patients. *Abstracts of the 18th Annual CAPD Conference*. 1998; 18: 1.
6. Mulatero C. W., **Bozcuk H.**, Oliver R.T.D., Mair G., Nargund V. Bladder sparing with synchronous combination chemo/radiotherapy in invasive bladder cancer. *Ann Oncol* 9:62-62, Suppl.4, 1998.
7. Turner BP., Sohaib SA., Hanson J., **Bozcuk H.**, Oliver R.T.D., Reznick R.H. Is 3D measurement of tumour volume valid, accurate and helpful technique in assessing response to chemotherapy? *European Radiology* 1999; 9:supplement 1, abst 955.
8. Owen N.J., Tsetsis D., **Bozcuk H.**, Oliver R.T.D., Reznick R.H. Day 21 Computerised Tomography Scan Response as a Predictor of Need for Post Chemotherapy Surgery in Nonseminomatous Germ Cell Tumour. *Radiology* 213 P: 306-306, 1999.
9. **Bozcuk H.**, Uslu G, Karaveli S, Samur M, Ozdogan M, Savas B. Predictors of distant metastasis at presentation in breast cancer: A retrospective study also evaluating associations among common biological indicators. *Ann Oncol* 11:37-37, Suppl.4, 2000.
10. **Bozcuk H.**, Martin C. Does treatment delay affect survival in Non- Small Cell Lung Cancer? *ESTRO* 2000

11. **Bozcuk H.**, Martin WMC. Does treatment delay affect survival in Non- Small Cell Lung Cancer? A retrospective analysis of delay and other factors. *Brit J Cancer* 83:43-43, Suppl. 1, 2000.
12. **Bozcuk H.**, Samur M, Ozdogan M, Yildiz M, Savas B. Determinants of quality of life in a group of cancer patients in Turkey. *MASCC* 2001.
13. Kurtoglu AU, Yücel G, Ataman F, **Bozcuk H.** The respiratory burst activity of neutrophils in patients of lung cancer treated by radiotherapy. *Free Radical Bio Med* 33: 75 Suppl. 1, 2002.
14. **Bozcuk H.**, Samur M, Koyuncu E, Yildiz M, Özdoğan M, Savaş B. A prediction model for the risk of intrahospital death in cancer patients: does it really work? *Proc Am Soc Clin Oncol*, Vol 21(1): 379-379, 2002.
15. Yalçın B, Üner A, Akbulut H, İçli F, Işıkdoğan A, Büyükçelik A, Dinçol D, Demirkazık A, **Bozcuk H.** A new schedule of Mitomycin-C and Vinorelbine combination in patients with metastatic breast cancer resistant to anthracyclines and taxanes: A phase II study. *Ann Oncol* 13: 68-68, Suppl 5, 2002.
16. Savaş B, Tanyel E, **Bozcuk H.**, Yeşilipek A, Karadoğan İ, Küpesiz A, Kurdoğlu E, Ündar L. Using MTT in vitro drug sensitivity test for the prediction of chemotherapy failure of leukemia patients. *Ann Oncol* 13:17-17, Suppl 5, 2002.
17. Ataman F, Uğur A, Yücel G, **Bozcuk H.**, Şimşir V. Effect of fractionated regional external beam radiotherapy on neutrophil subpopulations (in peripheral blood count) of cancer patients. *Radiotherapy and Oncology* 64:200-200, Suppl 1, 2002.
18. **Bozcuk H.**, Uslu G, Akan I, Samur M, Ozdogan M, Yildiz M, Artac M, Ozben T, Savas B. The association of chemotherapy response in metastatic breast cancer with growth factor pathways. *Proc Am Soc Clin Oncol*, Vol 22: A 149, 37-37, 2003.
19. Samur M, **Bozcuk H.**, Ozdogan M, Yildiz M, Artac M, Savaş B. What influences weight gain during adjuvant chemotherapy in women with breast cancer? *Proc Am Soc Clin Oncol*, Vol 22: A 292, 73-73, 2003.
20. Savas B, **Bozcuk H.**, Ozdogan M, Karaveli F, Pe E, Artaç M, Aykut A, Samur M. Molecular and clinical parameters which determine the docetaxel response in metastatic breast cancer. *Proc Am Soc Clin Oncol*, Vol 23: A 9732, 888-888, 2004.
21. **Bozcuk H.**, Dalnış B, Samur M, Savas B, Ozdogan M, Artac M, Yildiz M. Are baseline performance status and line of chemotherapy administration important for palliation of metastatic non-small cell lung cancer (NSCLC) with chemotherapy? *Proc Am Soc Clin Oncol*, Vol 23: A 8175, 768-768, 2004.
22. **Bozcuk H.**, Gumus A, Ozbilim G, Sarper A, Ozdogan M, Artac M, Samur M, Savas B. Recursive partitioning analysis of selected molecular markers to predict mediastinal lymph node involvement in operable NSCLC. *Proc Am Soc Clin Oncol*, A 7320, 2005.
23. Aksu G, **Bozcuk H.**, Kocun A, Sen CA. Does radiotherapy technique influence survival in rectal cancer? A multivariate analysis. *Eur J Cancer supplements*, A 704, 2005.
24. Ozdogan M, Samur M, Artac M, Yildiz M, Savas B, **Bozcuk H.** Factors effecting the disclosure practice of physicians treating cancer patients in Turkey. *Eur J Cancer supplements*, A 1331, 2005.
25. Artac M, Pehlivan S, Akcan S, Pehlivan M, Gelen T, Itirli G, Aksoy NH, Ozdogan M, Savas B, **Bozcuk H.** The value of pharmacogenomic analysis of microsatellite instability (MSI) and XPD, XRCC1 genotype polymorphisms to predict clinical outcome in metastatic colorectal carcinoma. *Proc Am Soc Clin Oncol*, A 13011, 2006.
26. **Bozcuk H.**, Artac M, Akcan S, Korgun DK, Ozben T, Ozdogan M, Samur M, Mutlu H, Kargi A, Savas B. Does serum VEGF predict prognosis in metastatic colorectal carcinoma patients treated with XELIRI? *Proc Am Soc Clin Oncol*, A 13548, 2006.
27. Artac M, **Bozcuk H.**, Afacan B, Ozdogan M, Timur M, Yildiz M, Samur M, Savas B. Metronomic cyclophosphamide – etoposide chemotherapy and serum VEGF level in metastatic breast cancer patients. *Ann Oncol* 17: 86-86, Suppl 9, 2006.
28. Artac M, Samur M, **Bozcuk H.**, Afacan B, Ozdogan M. The impact of waist to hip ratio on survival in metastatic breast cancer patients treated with aromatase inhibitors. *Proc Am Soc Clin Oncol*, A 1070, 2007.
29. **Bozcuk HS.**, Ozdogan M, Artac M, Yildiz M. Correlates of benefit from induction chemotherapy before radiotherapy in non-small cell lung cancer (NSCLC): a meta-analytical approach with meta-regression analysis. *Proc Am Soc Clin Oncol*, A 7575, 2008.
30. **Bozcuk H.**, Yildiz M, Ozdogan M, Coskun HS, Kargi A, Mutlu H, Uysal M, Savas B. Determinants of health service satisfaction among cancer patients and their caregivers in oncology services: a survey study from two teaching hospitals in Turkey. *Eur J Cancer supplements*, A 3613, 2009.
31. Ozdogan M, **Bozcuk H.**, Ozcan K, Tekeli A, Coskun HS, Kara A, Mutlu H, Kargi A, Uysal M, Savas B. The cancer education nursing unit's impact on informational needs of cancer patients-the first Turkish report. *Eur J Cancer supplements*, A 4242, 2009.
32. **Bozcuk H.**, Mutlu H, Artac M, Ozdogan M, Coskun HS, Kargi A, Uysal M, Savas B. An encouraging chemotherapy regimen in progressive small cell lung cancer. *Eur J Cancer supplements*, A 9130, 2009.
33. Ozdogan M, Kargi A, Artac M, **Bozcuk H.**, Boruban MC, Coskun HS, Mutlu H, Eren OO, Uysal M, Savas B. Maintenance semi-metronomic oral cyclophosphamide and oral etoposide regimen in extensive stage small-cell lung cancer patients after responding to first line treatment. *Eur J Cancer supplements*, A 9131, 2009.
34. Artac M, **Bozcuk H.**, Kiyici A, Eren OO, Boruban MC, Ozdogan M. Correlation of serum leptin level and waist-to-hip ratio with overall survival of patients with metastatic breast cancer treated with aromatase inhibitors. *Proc Am Soc Clin Oncol*, A 1106, 2010.
35. **Bozcuk H.**, Yildiz M, Ozdogan M, Coskun HS, Kaya C, Cakal S, Mutlu A, Ulukal E, Ay S, Kilickaya P. The associates of the risk of febrile neutropenia after conventional dose chemotherapy in patients with common cancers. A prospective study from two tertiary cancer centers. *Eur J Cancer supplements*, A 3015, 2011.
36. Artac M, Askın D, Kiyici A, Eren OO, Onel M, Boruban MC, **Bozcuk H.** Does obesity change the effect of aromatase inhibitors (AIs) on estradiol, leptin, insulin, and IGF-I serum levels in breast cancer patients? *J Clin Oncol* 30, 2012 (suppl: abstr 1008)

37. Uysal M, **Bozcuk H**, Goksu SS, Tatli AM, Arslan D, Gunduz S, Coskun HS, Ozdogan M, Savas B. Proteinuria as a predictive factor in metastatic colorectal cancer patients treated with bevacizumab. *J Clin Oncol* 30, 2012 (suppl abstr e14070)
38. Tatli AM, Coşkun HS, Uysal M, Goksu SS, Arslan D, Gunduz S, Ozdogan M, **Bozcuk H**, Savas B. Capecitabine plus bevacizumab as a maintenance treatment after induction treatment with folfox plus bevacizumab in metastatic colon cancer. *J Clin Oncol* 31, 2013(suppl; abstr e14683)
39. **Bozcuk H**, Yıldız M, Ucar S, Mutlu H, Coskun HS. The correlates of dose reduction in chemotherapy for patients with common cancers. A prospective study. *Ann Oncol* 2014; 25 (suppl_4): iv58-iv84. 10.1093/annonc/ndu326
40. Ayvaz F, Merdin A, Gunduz S, **Bozcuk H**, Coskun H. Opioid endocrinopathy: a clinical problem in cancer patients with pain. *Ann Oncol* 2014; 25 (suppl_4): iv517-iv541. 10.1093/annonc/ndu356
41. **Bozcuk H**, Ozcan K, Erdogan C, Mutlu H, Coskun HS. Effects of painting art therapy on quality of life and depression in cancer patients: a comparative study. *J Clin Oncol* 32, 2014 (suppl; abstr e17583)
42. Artac M, Geredeli C, Yıldırım S, Dede I, Inal A, Güler T, Boruban MC, Zamani AG, Demirkazık A, **Bozcuk H**. Relation of metastatic stage at the diagnosis of NSCLC to XRCC1 and TP53 SNPs. *J Clin Oncol* 2014; e19109.
43. Gligorov J, Bines J, Alba E, Mustachi G, Ciniere S, Gupta V, Pierga JY, **Bozcuk H**, Gaafar R, Gupta S, Vivanco GL, Wang X, Costa R, Altundag K, Chmielowska E, Ducla S, Freudenstung U, Cortes P, Doval D. Overall survival in the IMELDA randomized phase III trial of maintenance bevacizumab with or without capecitabine for her-2 negative metastatic breast cancer. *Cancer Res* 2015; 75 (9 suppl):p2-17-01.
44. Doval D, Ciniere S, Bozcuk H, Pierga JY, Altundag K, Wang X, Gupta S, Vivanco GL, Chmielowska E, Bines J, Montcuquet P, Namour A, Alba E, Mustacchi G, Cortes P, Ducla S, Freudenstung U, Fallowfield L, Gligorov J. Exploratory post hoc analyses of patient reported outcomes in the IMELDA randomized phase III trial: maintenance bevacizumab +/- capecitabine after initial first line bev plus docetaxel for her2- negative metastatic breast cancer. *Cancer Res* 2015; 75 (9 suppl):p2-12-16.
45. Ergen SA, Dinçbas H, Metcalfe E, Akyürek S, Yavas G, Ülger S, Özdenir BS, Yücel B, Oksuz DC, Senocak M, **Bozcuk H**. Patterns of failure and prognostic factors of the patients with LD SCLC according to the TNM staging. TOG-TROD study. *J Thoracic Oncol* 2016 (p1.07-043).

IN OTHER INDEXES

Papers :

1. Ustun H., Akca S., Altunbas H., **Bozcuk H.**, Ciftci F., Balci MK. Relationship between the Complications of Type 2 Diabetes Mellitus and Corrected QT in ECG(In Turkish). *Turkish Diabetes Annual*, 1997; 12:193-5.
2. Akca S., Ustun H., **Bozcuk H.**, Balci M.K., Yardimsever M., Ersoy F. 2 Years' Experience in Akdeniz University Medical Faculty Intensive Care Unit(In Turkish). *Cukurova University Medical Faculty Journal*, Vol.23:2, 1998; 82-7.
3. Ustun H., **Bozcuk H.**, Ustun M., Savas B. Comparison of antiemetic efficiency of ondansetron and metoclopramide in patients using non-cisplatin chemotherapy regimens. *Turkish Oncology Journal* 1999; 13(4): 109-11.
4. **Bozcuk H**, Coban E, Gelen T, Ozdogan M, Samur M, Savas B. An unusual case of massive hepatomegaly in a patient with peritoneal and pleural mesothelioma at the absence of hepatic involvement. Accepted by *Acta Oncologica Turcica* in 2001.
5. Ataman F, Korum AF, **Bozcuk H**, Şen CA, Samur M, Savas B, Aktan S. Postoperative adjuvant chemotherapy in the management of rectum cancer. *The journal for the diseases of colon and rectum*, 2003; 13: 51-56.
6. Ataman F, Şimşir V, Şen CA, **Bozcuk H**, Ögüş M, Erdoğan O, Savaş B. Preliminary results of pancreatic cancer patients with unresectable disease undergoing combined chemoradiotherapy. Accepted by *The Journal of Sisli Etfal Hospital*, in 2004

Abstracts and presentations:

Over 100 abstracts presented in national scientific meetings.

Citations

H factor = 20, and 1209 citations by *Google Scholar* as of 17.10.2017.

Book chapters written

"Cancer and Genetics" chapter written together with A. Nihat Bozcuk in "Genetics", Chapter 15, 295-304, Palme Kitapçılık, October 2000, Ankara, Turkey (In Turkish).

Book chapters translated

"Intoxication" chapter in "Mosby's Crash Course", Chapter 39, 387-390, Güneş Kitapçılık, 2001, Ankara, Turkey (Translation from English to Turkish).

Hobbies and Interests

Tennis, fishing, watercolour painting (1st personal exhibition (Antalya, 2011), playing the guitar & piano, martial arts, astronomy, social psychology.